Repaglinide and Ultracet drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Repaglinide (repaglinide) and Ultracet (acetaminophen; tramadol hydrochloride). Common drug interactions include oedema peripheral among females and hepatic encephalopathy among males.

The phase IV clinical study analyzes what interactions people have when they take Repaglinide and Ultracet. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Repaglinide?

Repaglinide has active ingredients of repaglinide. It is often used in diabetes. eHealthMe is studying from 8,226 Repaglinide users. Check the latest studies of Repaglinide.

What is Ultracet?

Ultracet has active ingredients of acetaminophen; tramadol hydrochloride. It is often used in pain. eHealthMe is studying from 6,351 Ultracet users. Check the latest studies of Ultracet.

On Jul, 30, 2026

18 people who take Repaglinide and Ultracet together, and have interactions are studied.

Repaglinide and Ultracet drug interactions.

What are the common drug interactions of Repaglinide and Ultracet, by gender? *:

female:

Oedema peripheral (superficial swelling)
Abnormal faeces (abnormal stool)
Acute respiratory failure
Aortic arteriosclerosis (hardening of the aortic arteries)
Aortic disorder
Arthralgia (joint pain)
Basophil count increased
Blood glucose increased
Blood magnesium increased
Blood potassium increased

male:

Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Septic shock (shock due to blood infection)
Hypokalaemia (low potassium)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
Pneumonia
Prostate cancer
Renal impairment (severely reduced kidney function)
Respiratory failure (inadequate gas exchange by the respiratory system)

What are the common drug interactions of Repaglinide and Ultracet, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Chronic kidney disease
Dyspepsia (indigestion)
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Hyperkalaemia (damage to or disease of the kidney)
Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Nephrogenic anaemia (anaemia due to kidney disease)
Renal failure (kidney dysfunction)
Renal injury (kidney injury)
Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
Arteriosclerosis coronary artery (thickening and hardening of arteries- coronary artery)

60+:

Pneumonia
Oedema peripheral (superficial swelling)
Blood potassium increased
Blood urea increased
Bone callus excessive (excessive bony deposit formed between and around the broken ends of bone fractures)
Contusion (a type of hematoma of tissue in which capillaries)
Femur fracture
Flatulence (flatus expelled through the anus)
Haemoglobin decreased
Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)

What are the existing conditions these people have? *

High Blood Pressure: 11 people, 61.11%
Back Pain: 10 people, 55.56%
Insomnia (sleeplessness): 6 people, 33.33%
Type 2 Diabetes: 5 people, 27.78%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 5 people, 27.78%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 5 people, 27.78%
Cough: 5 people, 27.78%
Diarrhea: 5 people, 27.78%
Dyslipidaemia (abnormal amount of lipids): 5 people, 27.78%
Hepatic Neoplasm Malignant (liver cancer): 5 people, 27.78%

* Approximation only. Some reports may have incomplete information.

Do you take Repaglinide and Ultracet?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously